Management of Helicobacter pylori.
Journal
Current opinion in gastroenterology
ISSN: 1531-7056
Titre abrégé: Curr Opin Gastroenterol
Pays: United States
ID NLM: 8506887
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
pubmed:
2
9
2020
medline:
16
10
2021
entrez:
2
9
2020
Statut:
ppublish
Résumé
Gastroenterologists and many general internists and primary care physicians confront questions regarding the management of Helicobacter pylori on a daily basis. The subject remains of global interest and continue to generate debate and research. Using the search terms 'pylori and treatment' or 'pylori and management' we identified over 1000 relevant articles in PubMed published over the time period 1 January 2019 to 30 April 2020. We have selected the most highly clinically relevant of these to review here. Clinical evidence grows regarding the benefits of H. pylori eradication on gastric cancer prevention. High rates of resistance to clarithromycin and levofloxacin, correlating with treatment failure in regimens utilizing these drugs, has stimulated interest in alternative regimens as well as the need for susceptibility testing of individual patients and populations. Although many aspects of H. pylori management are well established, implementation of appropriate testing and treatment pathways remains suboptimal throughout healthcare settings. Increased emphasis on measuring H. pylori-related clinical outcomes in practice is needed to identify implementation gaps, and to suggest means to best apply the knowledge gained on H. pylori for the prevention of gastric symptoms and disease.
Identifiants
pubmed: 32868505
doi: 10.1097/MOG.0000000000000678
pii: 00001574-202011000-00011
doi:
Substances chimiques
Anti-Bacterial Agents
0
Clarithromycin
H1250JIK0A
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
518-524Références
Fallone CA, Moss SF, Malfertheiner P. Reconciliation of recent Helicobacter pylori treatment guidelines in a time of increasing resistance to antibiotics. Gastroenterology 2019; 157:44–53.
Howden CW. Emerging regimens for H. pylori infection should enhance efficacy and circumvent resistance. Dig Dis Sci 2019; 64:2691–2692.
Du Y, Zhu H, Liu J, et al. Consensus on eradication of Helicobacter pylori and prevention and control of gastric cancer in China (2019, Shanghai). J Gastroenterol Hepatol 2020; 35:624–629.
Choi IJ, Kim CG, Lee JY, et al. Family history of gastric cancer and Helicobacter pylori treatment. N Engl J Med 2020; 382:427–436.
Li WQ, Zhang JY, Ma JL, et al. Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial. BMJ 2019; 366:l5016.
Lee YC, Chiang TH, Chou CK, et al. Association between Helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis. Gastroenterology 2016; 150:1113–1124.e5.
Ford AC, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta-analysis. Gut 2020; (In press).
Kumar S, Metz DC, Ellenberg S, et al. Risk factors and incidence of gastric cancer after detection of Helicobacter pylori infection: a large cohort study. Gastroenterology 2020; 158:527–536.e7.
Take S, Mizuno M, Ishiki K, et al. Risk of gastric cancer in the second decade of follow-up after Helicobacter pylori eradication. J Gastroenterol 2020; 55:281–288.
Zhao B, Zhang J, Mei D, et al. Does Helicobacter pylori eradication reduce the incidence of metachronous gastric cancer after curative endoscopic resection of early gastric cancer: a systematic review and meta-analysis. J Clin Gastroenterol 2020; 54:235–241.
El-Serag HB, Kao JY, Kanwal F, et al. Houston consensus conference on testing for Helicobacter pylori infection in the United States. Clin Gastroenterol Hepatol 2018; 16:992–1002.e6.
Gupta S, Li D, El Serag HB, et al. AGA clinical practice guidelines on management of gastric metaplasia. Gastroenterology 2020; 158:693–702.
Eusebi LH, Black CJ, Howden CW, et al. Effectiveness of management strategies for uninvestigated dyspepsia: systematic review and network meta-analysis. BMJ 2019; 367:l6483.
Guo CG, Cheung KS, Zhang F, et al. Incidences, temporal trends and risks of hospitalisation for gastrointestinal bleeding in new or chronic low-dose aspirin users after treatment for Helicobacter pylori: a territory-wide cohort study. Gut 2020; 69:445–452.
Hung KW, Knotts RM, Faye AS, et al. Factors associated with adherence to Helicobacter pylori testing during hospitalization for bleeding peptic ulcer disease. Clin Gastroenterol Hepatol 2020; 18:1091–1098.
Guo CG, Cheung KS, Zhang F, et al. Delay in retreatment of Helicobacter pylori infection increases risk of upper gastrointestinal bleeding. Clin Gastroenterol Hepatol 2020; (In press).
Hogh MB, Kronborg C, Hansen JM, et al. The cost effectiveness of Helicobacter pylori population screening-economic evaluation alongside a randomised controlled trial with 13-year follow-up. Aliment Pharmacol Ther 2019; 49:1013–1025.
Chen Q, Liang X, Long X, et al. Cost-effectiveness analysis of screen-and-treat strategy in asymptomatic Chinese for preventing Helicobacter pylori-associated diseases. Helicobacter 2019; 24:e12563.
Han Y, Yan T, Ma H, et al. Cost-effectiveness analysis of Helicobacter pylori eradication therapy for prevention of gastric cancer: a Markov model. Dig Dis Sci 2019; 65:1679–1688.
Kakiuchi T, Matsuo M, Endo H, et al. A Helicobacter pylori screening and treatment program to eliminate gastric cancer among junior high school students in Saga Prefecture: a preliminary report. J Gastroenterol 2019; 54:699–707.
Clines N, Beckman E. Development of a high throughput human stool specimen processing method for a molecular Helicobacter pylori clarithromycin resistance assay. PLoS One 2019; 14:e0224356.
Akashi T, Isomoto H, Matsushima K, et al. A novel method for rapid detection of a Helicobacter pylori infection using a gamma-glutamyltranspeptidase-activatable fluorescent probe. Sci Rep 2019; 9:9467.
Boltin D, Levi Z, Gingold-Belfer R, et al. Impact of previous exposure to macrolide antibiotics on Helicobacter pylori infection treatment outcomes. Am J Gastroenterol 2019; 114:900–906.
Alsamman MA, Vecchio EC, Shawwa K, et al. Retrospective analysis confirms tetracycline quadruple as best Helicobacter pylori regimen in the USA. Dig Dis Sci 2019; 64:2893–2898.
Kim SJ, Chung JW, Woo HS, et al. Two-week bismuth-containing quadruple therapy and concomitant therapy are effective first-line treatments for Helicobacter pylori eradication: a prospective open-label randomized trial. World J Gastroenterol 2019; 25:6790–6798.
Yang J, Zhang Y, Fan L, et al. Eradication efficacy of modified dual therapy compared with bismuth-containing quadruple therapy as a first-line treatment of Helicobacter pylori. Am J Gastroenterol 2019; 114:437–445.
Yu L, Luo L, Long X, et al. High-dose PPI-amoxicillin dual therapy with or without bismuth for first-line Helicobacter pylori therapy: a randomized trial. Helicobacter 2019; 24:e12596.
Choi YI, Chung JW, Park DK, et al. Tailored eradication vs empirical bismuth-containing quadruple therapy for first-line Helicobacter pylori eradication: a comparative, open trial. World J Gastroenterol 2019; 25:6743–6751.
Yu L, Luo L, Long X, et al. Susceptibility-guided therapy for Helicobacter pylori infection treatment failures. Therap Adv Gastroenterol 2019; 12:1756284819874922.
Gao C, Du SY, Fang L, et al. Eradication treatment of Helicobacter pylori infection based on molecular pathologic antibiotic resistance. Infect Drug Resist 2020; 13:69–79.
Graham DY, Lu H, Dore MP. Relative potency of proton-pump inhibitors, Helicobacter pylori therapy cure rates, and meaning of double-dose PPI. Helicobacter 2019; 24:e12554.
Lyu QJ, Pu QH, Zhong XF, et al. Efficacy and safety of vonoprazan-based versus proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis of randomized clinical trials. Biomed Res Int 2019; 2019:9781212.
Suzuki S, Gotoda T, Kusano C, et al. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan. Gut 2020; 69:1019–1026.
Laredo V, Sostres C, Alfaro E, et al. Management of Helicobacter pylori infection at the primary care level. The implementation of specific counseling improves eradication rates. Helicobacter 2019; 24:e12586.
Luo M, Hao Y, Tang M, et al. Application of a social media platform as a patient reminder in the treatment of Helicobacter pylori. Helicobacter 2020; 25:e12682.
McNicholl AG, O’Morain CA, Megraud F, et al. Protocol of the European Registry on the management of Helicobacter pylori infection (Hp-EuReg). Helicobacter 2019; 24:e12630.
McNicholl AG, Bordin DS, Lucendo A, et al. Combination of bismuth and standard triple therapy eradicates Helicobacter pylori infection in more than 90% of patients. Clin Gastroenterol Hepatol 2020; 18:89–98.
Kim BJ, Yang CH, Song HJ, et al. Online registry for nationwide database of Helicobacter pylori eradication in Korea: correlation of antibiotic use density with eradication success. Helicobacter 2019; 24:e12646.
Yokota N, Ae R, Amenomori M, et al. Clinical background factors affecting outcomes of Helicobacter pylori eradication therapy in primary care. J Gen Fam Med 2019; 20:139–145.
Serrano CA, Pierre R, Van Der Pol WJ, et al. Eradication of Helicobacter pylori in children restores the structure of the gastric bacterial community to that of noninfected children. Gastroenterology 2019; 157:1673–1675.
Sung JJY, Coker OO, Chu E, et al. Gastric microbes associated with gastric inflammation, atrophy and intestinal metaplasia 1 year after Helicobacter pylori eradication. Gut 2020; 69:1572–1580.
Liou JM, Chen CC, Chang CM, et al. Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial. Lancet Infect Dis 2019; 19:1109–1120.